Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elizabeth G Sumiec"'
Autor:
Zachary S Morris, Paul M Sondel, Amy K Erbe, Jacquelyn A Hank, Alexander L Rakhmilevich, Amber M Bates, Claire C Baniel, Elizabeth G Sumiec, Alexander A Pieper, Anna G Hoefges, Ravi B Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Some patients with cancer treated with anticancer monoclonal antibodies (mAbs) develop antidrug antibodies (ADAs) that recognize and bind the therapeutic antibody. This response may neutralize the therapeutic mAb, interfere with mAb effect
Externí odkaz:
https://doaj.org/article/cc4227e91f4b49f0a30308d759d06c22
Autor:
Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infilt
Externí odkaz:
https://doaj.org/article/ed62145c75cf435aa09efab35a43623c
Autor:
Claire C. Baniel, Clinton M. Heinze, Anna Hoefges, Elizabeth G. Sumiec, Jaquelyn A. Hank, Peter M. Carlson, Won Jong Jin, Ravi B. Patel, Raghava N. Sriramaneni, Stephen D. Gillies, Amy K. Erbe, Ciara N. Schwarz, Alexander A. Pieper, Alexander L. Rakhmilevich, Paul M. Sondel, Zachary S. Morris
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
In a syngeneic murine melanoma (MEL) model, we recently reported an in situ vaccination response to combined radiation (RT) and intra-tumoral (IT) injection of anti-GD2 hu14. 18-IL2 immunocytokine (IC). This combined treatment resulted in 71% complet
Externí odkaz:
https://doaj.org/article/69d352c38672413f9676b26e4741f6de
Autor:
Sarah E. Emma, Elizabeth G. Sumiec, Zachary S. Morris, Erin J. Nystuen, Kathleen A. O'Leary, Linda A. Schuler, Amber M. Bates
Publikováno v:
Cancer Research. 81:676-676
Metastatic, hormone therapy-resistant breast cancers expressing estrogen receptor (ER+) account for most breast cancer deaths. A lack of tumor-infiltrating lymphocytes (TILs) and low tumor mutation burden render most ER+ breast cancers immunologicall
Autor:
Justin C. Jagodinsky, Sarah E. Emma, Ravi B. Patel, Alexander A. Pieper, Joseph Grudzinski, Ian Marsh, Gustavo A. Sosa, Elizabeth G. Sumiec, Zachary S. Morris, Bryan P. Bednarz, Reinier Hernandez, Jamey Paul Weichert, Amber M. Bates, Erin J. Nystuen
Publikováno v:
Cancer Research. 81:679-679
We have observed in preclinical studies that the delivery of low dose targeted radionuclide therapy (TRT) therapy to sites of primary and metastatic cancer can improve the anti-tumor immune response to immune checkpoint inhibition (ICI) with anti-CTL
Autor:
Sarah E. Emma, Ian Marsh, Gustavo A. Sosa, Alexander A. Pieper, Justin C. Jagodinsky, Jamey Paul Weichert, Amber M. Bates, Bryan P. Bednarz, Reinier Hernandez, Zachary S. Morris, Erin J. Nystuen, Elizabeth G. Sumiec, Ravi B. Patel, Joseph Grudzinski
Publikováno v:
Cancer Research. 81:508-508
The purpose of this study was to evaluate mechanisms of cooperative therapeutic effects of bempegaldesleukin (BEMPEG; NKTR-214) and 90Y-NM600 in head and neck squamous cell carcinoma (HNSCC). BEMPEG is a first in class, CD122-preferential interleukin
Autor:
Elizabeth G. Sumiec, Claire C. Baniel, Alexander A. Pieper, Paul M. Sondel, Anna Hoefges, Amy K. Erbe, Jacqueline A Hank, Zachary S. Morris, Ravi Patel, Alexander L. Rakhmilevich, Amber M. Bates
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundSome patients with cancer treated with anticancer monoclonal antibodies (mAbs) develop antidrug antibodies (ADAs) that recognize and bind the therapeutic antibody. This response may neutralize the therapeutic mAb, interfere with mAb effecto
Autor:
Claire C. Baniel, Zachary S. Morris, Paul M. Sondel, Jacques Galipeau, Erin J. Nystuen, Elizabeth G. Sumiec, Sarah E. Emma, Amy K. Erbe, Amber M. Bates, Pradyut K. Paul, Alexander L. Rakhmilevich
Publikováno v:
Cancer Research. 80:902-902
We have recently demonstrated the effectiveness of combining external beam radiation therapy (RT), intratumoral immunocytokine (IT-IC), and anti-CTLA4 (αCTLA4) in eliminating large (500mm3) B78 melanomas (MEL), prolonging survival and invoking T cel
Autor:
Erin J. Nystuen, Zachary S. Morris, Elizabeth G. Sumiec, Sarah E. Emma, Kathleen A. O'Leary, Linda A. Schuler, Amber M. Bates
Publikováno v:
Cancer Research. 80:2255-2255
Metastatic, hormone therapy-resistant breast cancers expressing estrogen receptor (ER+) account for the majority of breast cancer deaths. ER+ breast cancers are immunologically “cold” with low tumor mutation burden and few tumor-infiltrating lymp
Autor:
Sarah E. Emma, Joseph Grudzinski, Zachary S. Morris, Jamey P. Weichert, Bryan Bednarz, Reinier Hernandez, Elizabeth G. Sumiec, Ian Marsh, Gustavo A. Sosa, Ravi Patel, Amber M. Bates, Alexander A. Pieper, Erin J. Nystuen
Publikováno v:
Cancer Research. 80:903-903
In preclinical studies, we have demonstrated that delivering low dose radiation therapy to all sites of metastatic cancer using targeted radionuclide therapy (TRT) can improve the response to immune checkpoint blockade. NM600 is a tumor-targeting alk